1 Graduate School of Guangxi University of Chinese Medicine, Nanning, China.
2 Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the Peoples Liberation Army, Nanning, China.
3 Graduate School of Guilin Medical University, Guilin, China.
4 People's Hospital of Guiping, Guiping, China.
5 People's Hospital of Hezhou, Hezhou, China.
Received: November 28, 2019
Accepted: March 3, 2020
Mediterr J Hematol Infect Dis 2020, 12(1): e2020021 DOI 10.4084/MJHID.2020.021
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: This study focused on the efficacy and safety of thalidomide for patients with β-thalassemia in a multicenter trial.
Several promising fetal hemoglobin (HbF) inducers, including hydroxyurea, erythropoietin, 5-azacytidine, and sodium butyrate,[4,6] have achieved limited success for the treatment of β-thalassemia to date. Hydroxyurea, approved by the FDA for the treatment of sickle cell disease (SCD), is also the most widely used HbF inducer in β-thalassemia. However, the clinical application of hydroxyurea is limited by the low number of significant responders,[7,8] reduced clinical response with long follow-up,[9,10] and bone marrow suppression. Therefore, better treatments facilitating improved outcomes are increasingly important. Thalidomide, a synthetic glutamic acid derivative, is widely used as an immunomodulator for the treatment of various hematological cancers due to its anti-inflammatory, anti-angiogenic, and anti-tumor effects. Moreover, thalidomide is an HbF inducer that promotes γ-globin gene expression.[13,14] A few case reports and retrospective analyses have documented significant effects of thalidomide on NTDT or TDT,[15-20] that our group subsequently confirmed in a clinical trial. However, the reliability of these studies was softened by the few patients studied and short-term follow-up. In the current study, we analyzed the efficacy and safety of thalidomide for β-thalassemia in a relatively large patient sample over a long-term follow-up period.
Patients and Methods
The initial dose of thalidomide used was 50 mg/d, and a daily dose of 100 mg/d was given to patients needing blood transfusions at least twice a month. Aspirin (100 mg/d) was prescribed to patients post-splenectomy or those with platelet counts >500 × 109/L to prevent thrombosis. Patients were regularly followed up monthly during the first three months of treatment and every 2-3 months afterward. Baseline and follow-up records were reviewed for demographic data, transfusion history, splenic size, adverse reaction, and duration of therapy. A halving of the dosage was prescribed in cases where side effects were graded III or above. For patients who failed to respond, 50% of the current dose was increased every month after 3 months of treatment. If no response was observed within 6 months, thalidomide was discontinued, and the patient advised to resume conventional management. Within the four research centers, complete blood counts were analyzed using an XE 5000 automatic blood cell analyzer (Sysmex Corporation, Kobe, Japan). Different Hb levels were quantified using Bio-Rad Variant II high-pressure liquid chromatography (HPLC) (Bio-Rad, Hercules, CA, USA). Biochemical parameters and serum ferritin levels (SF) were assessed using a multichannel analyzer (Abbot Aeroset, Abbott Diagnostics, Bohemia, NY, USA) and chemiluminescence (Beckman Coulter, Inc., CA, USA).
Standard for determination of efficacy. For patients with NTDT, response to thalidomide was defined as follows: Main Responder (MaR) showing an increase in Hb level >2.0g/dl, Minor Responder (MiR) achieving elevation in Hb level of 1.0-2.0g/dl, and No Responder (NR) showing a <1g/dl increase in Hb level. For patients with TDT, the groups were defined by the following parameters: MaR, removal from the blood transfusion, MiR, ≥50% reduction in transfusion requirement, and NR, <50% reduction in transfusion requirement.[4,7]
Statistical analysis. SPSS Statistics 21.0 (SPSS Inc., Chicago, IL, USA) was applied for data analysis. Numerical data were presented as means ± SD or median and interquartile range (IQR). A paired t-test or Mann-Wilcoxon rank-sum test was applied to compare the changes in continual variables before and after treatment. Comparisons in numerical variables between two groups were performed with Student’s t-test or Mann-Whitney rank-sum test. Hb levels were assessed for comparability at each time-point using repeated measures analysis of variance (ANOVA). Chi-square or Fisher exact test was used to compare categorical variables for small sample size, followed by logistic regression using significant results from univariate analysis to confirm the association. P values <0.05 were considered statistically significant.
Clinical features. In our cohort, alleviation of fatigue, and an increase in the energy state, well-being, and physical activity was detected in 88.7% (55/62) of the patients. Facial changes were observed in 69.4% (43/62) of the patients at the end of the study. In nonsplenectomized responders, average spleen size (length × width) was not significantly altered (110.1±20.3 cm2 vs 114.7±29.6 cm2, n=14, P=0.493).
Short-term follow-up. After a 3-month treatment period, 62.9% (39/62) and 30.6% (19/62) of the patients showed MaR and MiR status, respectively, while 6.5% (4/62) were classified as NR. As shown in Table 1, for patients with NTDT, the Hb level increased from a baseline mean of 6.8±1.1 g/dl to 9.7±1.9 g/dl (P<0.001), with an average increase of 2.9±1.6g/dl. Elevated Hb was mainly attributable to increased HbF levels. The average HbF percentage increased from a pretreatment level of 41.9±23.4% to 54.3±23.0% (P<0.001) after treatment. Among patients with TDT, transfusions were terminated in 43.5% (10/23) of the patients and decreased by more than 50% in 52.2% (12/23) of the patients, an increase in the average hemoglobin concentration was contemporarily observed. There was a significant drop in yearly transfusions from 20.7±7.7 to 5.8±6.8 blood units per year. After treatment, the red blood cell (RBC) count was markedly increased, nucleated red blood cells (NRBC) were significantly decreased, and reticulocyte counts were not significantly changed. As mean cell volume (MCV) decreased, mean corpuscular Hb concentration (MCHC) significantly increased. Parameters reflecting hemolysis, including bilirubin and lactate dehydrogenase (LDH), showed a significant decrease. However, after the treatment, the overall average SF was not decreased but increased to a significant extent.
|Table 1. Laboratory data of the patients with β-thalassemia and treatment with thalidomide.|
Long-term follow-up. Four NRs among the 62 patients discontinued therapy, respectively, after 3-6 months. Table 1 depicts the changes in clinical and laboratory efficacy indicators of patients with NTDT or TDT after long-term follow-up. In total, 34 of the 58 responders were treated with thalidomide for >12 months, averaging 21.9±6.7 months (12-37 months). In 28 responders, the long-term follow-up response was not significantly different from the 3-month response. Among the remaining six patients, two showed a decreased therapeutic effect, changing from MaR to MiR status, and four improved from MiR to MaR. Repeated measures ANOVA showed that Hb levels at different follow-up time points of 3 and 12 months after treatment increased significantly, compared with baseline values in NTDT (F=58.682, P<0.001) and TDT (F=22.259, P<0.001), with no significant differences between the 3 and 12-month period (P>0.05) (Figure 1).
|Figure 1. Hemoglobin levels of the patients receiving thalidomide therapy.|
The duration of therapy for 11 patients exceeded 24 months, with an average treatment period of 30.1±3.8 months (range 24-37 months). Ten patients maintained clinical response during the observation period, and only one changed status from MaR to MiR. Similarly, Hb levels of the groups at different follow-up time-points (3, 12, and 24 months) were significantly increased compared with baseline levels (NTDT: F=29.411, P<0.001; TDT: F=15.835, P=0.001). Average Hb was comparable at 3, 12, and 24 months (P>0.05) (Figure 1).
Effect of dose adjustment on Hb. In total, seven patients experienced dose reduction during treatment. The levels of Hb before and after reduction are shown in Figure 2a. Two patients with doses reduced from 100 to 50 mg/d maintained constant levels of Hb. The Hb level decreased in the remaining four patients for whom the dose was reduced from 50 to 25 mg/d, but three retained MaR status, and only one changed to MiR.
Interestingly, one patient required multiple dose adjustments from the initial 50 to 25 mg/d, which was subsequently reduced to 12.5 mg/d, and finally, 12.5 mg/q.d., with the maintenance of Hb level at >9 g/dl, and while the Hb levels decreased after drug withdrawal, it was restored after resuming treatment (Figure 2c). Only two patients were administered increased doses during treatment. In order to no deviate from blood transfusion, one patient increased the dose from 50 to 100 mg/d and reached MiR; no improvement was observed in another patient, even upon increasing the dose from 100 to 150 mg/d.
Effect of drug withdrawal on Hb. Treatment was discontinued in 14 patients (seven MaR, three MiR, and four NR). Within the responders, two patients discontinued the drug due to constipation and menstruation disorders while the others discontinued treatment because they could not insist on drug intake or were preparing for conception. The changes in Hb in 10 responders before and after drug withdrawal are presented in Figure 2b. Regardless of the length of treatment, the Hb level was significantly decreased after drug discontinuation for one month and further declined to baseline levels with the extension of withdrawal time.
Predictors of response. To identify potential predictors of the thalidomide response, we divided all patients into two groups (MaR and MiR+NR). The primary response to thalidomide was significantly correlated with the HbF ratio before treatment (P=0.003) and splenic status (P=0.025), but not related to age, sex, phenotype, duration of treatment, thalidomide dose or baseline Hb level (Table 2). To view the effect of blood transfusion on hemoglobin, the authors analyzed patients with NTDT, separately. Logistic regression analysis identified the ratio of HbF at baseline (P=0.038, OR=1.111, 95% CI: 1.006-1.226) as an independent risk factor for the main response to thalidomide.
|Table 2. Predictors of thalidomide response among patients with β-thalassemia.|
Toxicity. The mild adverse effects of thalidomide were recorded in 10 patients. The most common toxicity was at the gastrointestinal level (5/62) followed by a rash (2/62) and menstruation disorders (2/62), but the symptoms were transient and recovered after symptomatic treatment or temporary drug discontinuance. During long-term follow-up, one patient developed peripheral neurotoxicity with intermittent numbness of both lower limbs. Potential underlying conditions or diseases responsible for peripheral neurotoxicity were ruled out. The initial dose of thalidomide administered was 100 mg/d for 23 months, and the cumulative dose was ~ 55 g. Distal numbness of both lower limbs occurred about 18 months after therapy, and these symptoms were incompletely reversed after drug withdrawal over a subsequent 4-month period. During the treatment period, no hematological toxicity or bone marrow suppression was detected in patients. Furthermore, thalidomide had no unfavorable effects on liver or kidney function and induced no significant changes in alanine aminotransferase (ALT) or creatinine (Cr) levels.
Although the use of thalidomide to treat β-thalassemia has achieved good results, there is still no consensus on the optimal and maintenance dose for clinical application. At present, the therapeutic dose of thalidomide for β-thalassemia is ~50-100 mg/d,[15-17,19,20] and the dose-response relationship is yet to be established. Compared with a daily dose of 50 mg/d, we observed that the dose increment did not give significant added benefit. For responders who received maintenance therapy at a relatively low dose, the response was evident despite a decrease in Hb levels. Interestingly, Hb decreased rapidly to the baseline level after drug withdrawal and was restored after the re-introduction of the drug, consistent with the results of Fozza at el. Therefore, thalidomide seems to have a “switching effect” on β-thalassemia, and the maintenance dose could be reduced in the future. Since patients with thalassemia require lifelong medication, it may be valuable to compare the effects of thalidomide with a different maintenance dose.
Limited complications were reported in β-thalassemia, with peripheral neuropathy, which is one of the most feared complications, being documented in one patient. The mechanism of thalidomide-induced neurotoxicity remains to be clarified. Several studies have explored risk factors for thalidomide neuropathy, including age, daily dose, duration of drug exposure, cumulative dose, and preexisting neuropathy. The incidences of peripheral neurotoxicity that have been reported are relatively low and are limited at a daily dose of >50 mg.[27-29] Although only one patient presented with peripheral neurotoxicity in our study, physicians contemplating its use should be vigilant to its occurrence and take preventive action. Furthermore, it is valuable to explore lower therapeutic or maintenance doses to maximize the benefit/risk rate.
The current study is the first to assess the efficacy and safety of thalidomide in a relatively large cohort over a long-term follow-up period and provide new insights on the continued efficacy and safety of thalidomide in patients with β-thalassemia.
A limitation of this study was its design, having included patients from three centers. Nevertheless, the effects of this limitation were attenuated by the fact that all centers used 1) the same inclusion criteria, 2) equal treatment and management of patients, and 3) the long duration of follow-up.
- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018. 391(10116): 155-167. https://doi.org/10.1016/S0140-6736(17)31822-6
- Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995. 80(1): 58-68.
AT, Radwan A, Viprakasit V. When to consider transfusion therapy for
patients with non-transfusion-dependent thalassaemia. Vox Sang. 2015.
108(1): 1-10. https://doi.org/10.1111/vox.12201 PMid:25286743 PMCid:PMC4302976
KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with
fetal hemoglobin induction therapy in patients with β-thalassemia.
Blood. 2013. 121(12): 2199-212; quiz 2372. https://doi.org/10.1182/blood-2012-10-408021 PMid:23315167
Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing
of human hematopoietic stem cells. Nat Med. 2019. 25(5): 776-783. https://doi.org/10.1038/s41591-019-0401-y PMid:30911135 PMCid:PMC6512986
A, Alimirzoyeva Z, Hasanova M, Mammadova T, Shirinova A. Clinical
application of recombinant erythropoietin in beta-thalassaemia
intermedia. Georgian Med News. 2016. (255): 86-92.
A, El-Ghamrawy M, EL-Ela MA, et al. Response to hydroxycarbamide in
pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt. Ann
Hematol. 2014. 93(12): 2045-50. https://doi.org/10.1007/s00277-014-2154-5 PMid:25062719
M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship
of patients with β-thalassemia taking hydroxyurea: a 13-year experience
in Iran. Int J Hematol. 2012. 95(1): 51-6. https://doi.org/10.1007/s12185-011-0985-6 PMid:22180324
P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxycarbamide
following long-term treatment of thalassaemia intermedia as observed in
vivo and in primary erythroid cultures from treated patients. Br J
Haematol. 2010. 151(5): 509-15. https://doi.org/10.1111/j.1365-2141.2010.08397.x PMid:20955403
A, Maggio A, Renda D, Di Marzo R, Rigano P. Treatment with
hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in
some patients during long-term follow up. Br J Haematol. 2006. 133(1):
105-6. https://doi.org/10.1111/j.1365-2141.2006.06002.x PMid:16512837
MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A.
Hydroxyurea-induced hematological response in transfusion-independent
beta-thalassemia intermedia: case series and review of literature.
Pediatr Hematol Oncol. 2009. 26(8): 560-5. https://doi.org/10.3109/08880010903271671 PMid:19954365
- Stewart AK. Medicine. How thalidomide works against cancer. Science. 2014. 343(6168): 256-7. https://doi.org/10.1126/science.1249543 PMid:24436409 PMCid:PMC4084783
FMA, Dehghani FA, Hajizamani S, Mossahebi-Mohammadi M, Yaghooti H, Saki
N. Thalidomide is more efficient than sodium butyrate in enhancing
GATA-1 and EKLF gene expression in erythroid progenitors derived from
HSCs with β-globin gene mutation. Int J Hematol Oncol Stem Cell Res.
2016. 10(1): 37-41.
- Aerbajinai W, Zhu J,
Gao Z, Chin K, Rodgers GP. Thalidomide induces gamma-globin gene
expression through increased reactive oxygen species-mediated p38 MAPK
signaling and histone H4 acetylation in adult erythropoiesis. Blood.
2007. 110(8): 2864-71. https://doi.org/10.1182/blood-2007-01-065201 PMid:17620452 PMCid:PMC2018668
C, Pardini S, Giannico DB, et al. Dramatic erythroid response to
low-dose thalidomide in two patients with transfusion independent
thalassemia and severe post-transfusional alloimmune hemolysis. Am J
Hematol. 2015. 90(7): E141. https://doi.org/10.1002/ajh.24030 PMid:25850682
P, Costantini S, Spasiano A, et al. The long-term and extensive
efficacy of low dose thalidomide in a case of an untransfusable patient
with Non-Transfusion-Dependent Thalassemia. Blood Cells Mol Dis. 2016.
57: 97-9. https://doi.org/10.1016/j.bcmd.2016.01.003 PMid:26810455
J, Zhu W, Cai N, Bu S, Li J, Huang L. Thalidomide induces haematologic
responses in patients with β-thalassaemia. Eur J Haematol. 2017. 99(5):
437-441. https://doi.org/10.1111/ejh.12955 PMid:28850716
Y, Ren Q, Zhou Y, Li P, Lin W, Yin X. Thalidomide has a significant
effect in patients with thalassemia intermedia. Hematology. 2018.
23(1): 50-54. https://doi.org/10.1080/10245332.2017.1354427 PMid:28718348
LB, Delgado-Lamas JL, Rubio-Jurado B, Perea FJ, Ibarra B. Thalidomide
therapy in a patient with thalassemia major. Blood Cells Mol Dis. 2008.
41(1): 136-7. https://doi.org/10.1016/j.bcmd.2008.03.001 PMid:18439858
N, Tavecchia L, Capra M, et al. Optimal response to thalidomide in a
patient with thalassaemia major resistant to conventional therapy.
Blood Transfus. 2010. 8(1): 63-5. https://doi.org/10.7175/cmi.v4i2.531
Q, Zhou YL, Wang L, et al. Clinical trial on the effects of thalidomide
on hemoglobin synthesis in patients with moderate thalassemia
intermedia. Ann Hematol. 2018. 97(10): 1933-1939. https://doi.org/10.1007/s00277-018-3395-5 PMid:29931453
M, Zafari M, Alipur A, Hedayatizadeh-Omran A. The effect and side
effect of hydroxyurea therapy on patients with β-thalassemia: a
systematic review to December 2012. Hemoglobin. 2014. 38(4): 262-71. https://doi.org/10.3109/03630269.2014.927770 PMid:25023087
F, Sun M, Zhang X, et al. Molecular epidemiological survey of
haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern
China. Clin Genet. 2010. 78(2): 139-48. https://doi.org/10.1111/j.1399-0004.2010.01430.x PMid:20412082
XL, Wu ZK, He YY, Zhou TH, Zhou YL, Zhang XH. Treatment and
complications of thalassemia major in Guangxi, Southern China. Pediatr
Blood Cancer. 2011. 57(7): 1174-8. https://doi.org/10.1002/pbc.23101 PMid:21394896
L, Yong L, Xue L, Jiayou Z. Economic Evaluation of Chelation Regimens
for β-Thalassemia Major: a Systematic Review. Mediterr J Hematol Infect
Dis. 2019. 11(1). https://doi.org/10.4084/mjhid.2019.036 PMid:31308912 PMCid:PMC6613630
Sanctis V, Soliman AT, Canatan D, et al. Thyroid Disorders in
Homozygous β-Thalassemia: Current Knowledge, Emerging Issues and Open
Problems. Mediterr J Hematol Infect Dis. 2019. 11(1): e2019029. https://doi.org/10.4084/mjhid.2019.029 PMid:31205633 PMCid:PMC6548211
P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N.
Thalidomide in patients with malignant pleural mesothelioma. Lung
Cancer. 2005. 48(2): 291-6. https://doi.org/10.1016/j.lungcan.2004.10.005 PMid:15829331
S, Ochonisky S, Bouche P, et al. Incidence and risk factors for
thalidomide neuropathy: a prospective study of 135 dermatologic
patients. J Invest Dermatol. 2002. 119(5): 1020-6. https://doi.org/10.1046/j.1523-1747.2002.19502.x PMid:12445187
- Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014. 40(7): 872-82. https://doi.org/10.1016/j.ctrv.2014.04.004 PMid:24830939